We will objectively assess the financial situation of selectedpharmaceutical companies: DHG - Hau Giang Pharmaceutical Joint Stock Company, DCL - CuuLong Pharmaceutical Joint Stock Compa
Trang 1GROUP ASSIGNMENT Analysis Of Financial Statements Of Companies In the Pharmaceutical Industry Within Three Years Of
2020, 2021 And 2022 Subject: ACC101
Class: MC1805
Lecturer: Tô Thị Thùy Dương
Group Member:
Huỳnh Mạnh Cường - SS170340
Trần Nguyễn Hoàng Anh - SE173276
Lê Anh Quân - SE173047
Nguyễn Thị Lan Anh - SS170762
Lê Thị Thu Hương - SS170196
Võ Xuân Anh Quân - SE140236
Trang 2Table of Content
1 DHG - Hau Giang Pharmaceutical Joint Stock Company 3
2 DCL - Cuu Long Pharmaceutical Joint Stock Company 3
4 IMP - IMEXPHARM Pharmaceutical Joint Stock Company 4
Trang 3I Abstract:
We wrote this report for the purpose of comparing the financial statements of pharmaceuticalcompanies by applying the learned ratios We will objectively assess the financial situation of selectedpharmaceutical companies: DHG - Hau Giang Pharmaceutical Joint Stock Company, DCL - CuuLong Pharmaceutical Joint Stock Company, OPC - Pharmaceutical Joint Stock Company OPCproducts, IMP - IMEXPHARM Pharmaceutical Joint Stock Company
1 DHG - Hau Giang Pharmaceutical Joint Stock
Company
- The predecessor of Hau Giang Pharmaceutical Joint Stock
Company is 2/9 Pharmaceutical Factory, established on
September 2, 1974 at Kenh 5 Dat Set, Khanh Lam
commune (now Khanh Hoa commune), U Minh district,
Ca Mau province Quickly
- September 2, 2004: Hau Giang Pharmaceutical Complex
Enterprise, City Can Tho transformed its operating model into Hau Giang PharmaceuticalJoint Stock Company and officially went into operation with an initial charter capital of VND
2 DCL - Cuu Long Pharmaceutical Joint Stock Company
- Cuu Long Pharmaceutical Joint Stock Company, formerly
known as Cuu Long Pharmaceutical Enterprise, was established
in 1976
- In 1992, after Cuu Long province split into Vinh Long and Tra
Vinh provinces, the company changed its name to Cuu Long
Pharmaceutical and Medical Supplies Company
- In August 2004, the Company was equitized and officially
transformed into a joint stock company from January 1, 2005
with the name of CAU LONG PHARMACEUTICAL JOINT
STOCK COMPANY (PHARIMEXCO)
- On September 17, 2008, DCL shares were officially listed and traded on the Ho Chi MinhCity Stock Exchange HCM
Business activities:
- Manufacturing, trading and direct import and export: pharmaceuticals, capsules, tools,medical equipment for the pharmaceutical industry, medical industry, cosmetics, nutritionalfoods, medicinal materials, chemicals, raw materials raw materials and other pharmaceuticalpreparations
- Producing all kinds of packaging used in the pharmaceutical industry
- Cultivation of medicinal herbs
Trang 4- Trading and performing information technology services.
3 OPC - OPC Pharmaceutical Joint Stock Company
- OPC Pharmaceutical Joint Stock Company, formerly known as TW
26 Pharmaceutical Enterprise - OPC, was established in October
1977 under Decision No 1176/BYT-QD dated October 24, 1977 of
the Ministry of Health from the merger 8 private apothecaries in
Saigon formerly
- On February 8, 2002, the Prime Minister issued Decision No
138/QD-TTg on the transformation of Central Pharmaceutical
Enterprise 26 under the Vietnam Pharmaceutical Corporation
-Ministry of Health into OPC Pharmaceutical Joint Stock Company
The initial charter capital of the Company upon equitization is 20 billion VND, of which thestate holding rate is 29%
- On October 20, 2008, the Ho Chi Minh Stock Exchange issued an official letter approving theregistration of listing shares for OPC Pharmaceutical JSC, business registration certificate No
4103000893 issued by the City Department of Planning and Investment First issued by HoChi Minh City on March 25, 2002, with the sixth change on January 18, 2008, charter capital:VND 81,900,000,000, official transaction date October 30, 2008
Business activities:
- Trading, planting and processing medicinal herbs;
- Manufacturing and trading in pharmaceuticals, supplies, medical machinery and equipment,chemicals, cosmetics, food, food
- functional products, wine and alcoholic beverages, carbonated drinks;
- Prepare prescription drugs;
- Consulting, scientific and technical services, technology transfer in the field of medicine andpharmacy;
- Import and export business in the field of medicine and pharmacy;
4 IMP - IMEXPHARM Pharmaceutical Joint Stock Company
- The predecessor of Imexpharm pharmaceutical company is Dong
Thap Pharmaceutical Union Enterprise, under the Dong Thap
Department of Health In November 1992, Dong Thap
Pharmaceutical Union was renamed as Dong Thap
Pharmaceutical Company, under Dong Thap People's Committee
- November 1999 Dong Thap Pharmaceutical Company changed its
name to Central Pharmaceutical Company 7 under the Vietnam
Pharmaceutical Corporation
- In July 2001, Central Pharmaceutical Company 7 changed into
Imexpharm pharmaceutical company with charter capital of 22 billion VND
- The company started listing with the code IMP on December 4, 2006 on the Ho Chi MinhCity Stock Exchange
- Provide warehouse system services for storing drugs and medicinal ingredients
- Cultivation, processing and trading of medicinal herbs
Trang 5III Data analysis:
b Formula:
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐿𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠The current ratio is less than 1: may imply that the company is having difficulty paying off itsshort-term debt and may need to use other sources of funding such as borrowing or selling assets topay it off This could indicate an unstable financial situation and could pose a risk in keeping thebusiness afloat
The current ratio is equal to 1: may indicate that the company is operating at a minimum level tomaintain its ability to pay its debts This can pose some risk, especially during a financial crisis orwhen there are sudden fluctuations in cash flows If the company is in financial trouble, paying offdebt can become difficult and lead to serious financial problems
The current ratio is greater than 1: The company has the ability to pay short-term liabilities with itscurrent assets A current ratio greater than 1 indicates a company is more financially viable and lessdependent on borrowing or selling assets to pay off debt
c Data from selected companies:
DHG - Hau Giang Pharmaceutical Joint Stock Company
Current assets 3.475.797.124.506 3.720.882.994.624 4.218.772.327.716Current Liabilities 878.652.181.871 757.700.006.863 811.536.702.268
DCL - Cuu Long Pharmaceutical Joint Stock Company
Current assets 1.028.307.485.392 838.210.231.273 962.346.195.866Current Liabilities 280.007.773.941 600.623.688.861 476.721.469.516
OPC - OPC Pharmaceutical Joint Stock Company
Current assets 484.836.537.434 601.100.535.457 635.592.351.771Current liabilities 202.262.867.143 271.021.414.762 161.137.789.769
Trang 62020 2021 2022Current assets 981.975.300.723 1.176.339.787.490 1.103.552.901.572Current liabilities 346.969.098.434 408.638.192.302 382.496.674.756
d Evaluate:
In general, DHG, DCL, OPC and IMP companies all have stable and quite high current ratios,
showing relatively good short-term debt solvency However, there are still differences between
companies:
- The current ratio of DHG in all three years is high, from 4.0 to 5.2 This shows that thecompany is able to pay off its short-term debt with its short-term assets easily DHG hassufficient short-term assets to meet its short-term liabilities without using additional fundingsources
- The current ratio of DCL has fluctuated significantly from 2020 to 2022 In 2021, the currentratio decreased significantly to 1.4, while in 2022, it increased to 2.0 A current ratio lowerthan 1 in 2021 may indicate that the company is having difficulty paying off its short-termdebt with its current assets, and may need to find additional funding
- Current ratio of OPC and IMP in all three years are stable from 2.2 to 3.9 and 2.8 to 2.9 Thisratio shows that the company is able to pay off its short-term liabilities with its current assetswith relative ease OPC and IMP have good financial flexibility and ability to maintainliquidity
B Acid-test ratio:
a Definition:
The Acid-Test Ratio, also known as the quick ratio, is a liquidity ratio that measures how sufficient acompany’s short-term assets are to cover its current liabilities In other words, the acid-test ratio is ameasure of how well a company can satisfy its short-term (current) financial obligations
b Formula:
𝐴𝑐𝑖𝑑 − 𝑡𝑒𝑠𝑡 𝑟𝑎𝑡𝑖𝑜 = 𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠𝑄𝑢𝑖𝑐𝑘 𝐴𝑠𝑠𝑒𝑡𝑠 = 𝐶𝑎𝑠ℎ + 𝑆−𝑇 𝐼𝑛𝑣𝑒𝑠𝑡𝑚𝑒𝑛𝑡𝑠 + 𝑅𝑒𝑐𝑒𝑖𝑣𝑎𝑏𝑙𝑒𝑠
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠Acid-test ratio less than 1: This indicates that the company has the ability to pay short-term
liabilities with assets that are easily convertible into cash The company may have to rely on sellinglong-term assets or using other sources of funding to secure debt payments An Acid-test ratio of lessthan 1 may indicate an unstable debt payment situation and may pose a financial risk
The acid-test ratio is equal to 1: This means that the value of a company's current assets that arereadily convertible into cash is sufficient to cover its short-term liabilities Although the company hasthe ability to pay off debt, there is no excess to ensure flexibility in debt repayment An Acid-test ratio
Trang 7of 1 can indicate that the company is maintaining a minimum level to ensure debt solvency, but mayface difficulties in an unexpected situation or financial crisis.
Acid-test ratio greater than 1: This means that the company has the ability to pay its short-termliabilities with assets that are easily convertible into cash An Acid-test ratio greater than 1 indicatesthat the company is able to pay off debt easily and flexibly, without the need to use additional fundingsources or sell assets This shows a stable financial situation and the ability to cope with unexpectedfluctuations
c Data from selected companies:
DHG - Hau Giang Pharmaceutical Joint Stock Company
Short term
investment 2.074.000.000.000 2.110.000.000.000 2.355.000.000.000Current
receivable 496.020.199.824 488.071.438.874 550.503.358.957Current
receivable 252.304.346.512 179.934.712.264 495.512.807.843Current
investment 68.954.572 68.954.572 209.968.954.572Current
receivable 137.123.155.715 127.243.186.490 171.928.713.130Current liabilities 202.262.867.143 271.021.414.762 161.137.789.769
Trang 82020 2021 2022Cash 85.268.705.365 271.272.865.376 178.845.070.328Short term
investment 63.607.855.260 112.452.800.000 211.300.000.000Current
receivable 398.091.289.641 295.062.515.167 270.938.803.795Current liabilities 346.932.038.104 408.638.192.302 352.496.674.756
- OPC: OPC's acid-test ratio has increased significantly from 2020 to 2022 This indexincreased from 0.9 to 2.8, showing the company's ability to pay short-term liabilities withassets easily converted into cash with relative ease and flexibility
C Day’s Sales in Inventory:
a Definition:
Days' Sales in Inventory (DSI) is a financial metric used to measure the average number of days ittakes for a company to sell its inventory It is also referred to as the number of days' inventory onhand
b Formula:
𝐷𝑎𝑦𝑠’ 𝑆𝑎𝑙𝑒𝑠 𝑖𝑛 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑔𝑜𝑜𝑑𝑠 𝑠𝑜𝑙𝑑 * 365
c Data from selected companies:
DHG - Hau Giang Pharmaceutical Joint Stock Company
Average Inventory 826.585.429.976 950.806.732.036.5 1,161,719,714,080COGS 1.944.243.042.082 2.082.259.824.914 2.418.521.064.699Day’s Sales in
Inventory
Trang 92020 2021 2022Average Inventory 215,169,227,178 254,900,360,421 299,302,695,816
- DHG's DSI increased from 2020 to 2022, suggesting that the company maintains inventoryfor a longer period of time before selling it off However, the DSI value is still relatively low,showing that the company has the ability to consume inventory efficiently
- DCL's DSI increased from 2020 to 2021, but decreased significantly in 2022 DCL's DSIvalue in 2022 is the lowest in years, showing that the company consumes inventory quickly
- OPC's DSI declined continuously from 2020 to 2022, indicating that the company consumedinventory faster over time OPC's DSI value in 2022 is the lowest in years, showing that thecompany manages its inventory effectively
- IMP's DSI increased from 2020 to 2021, but decreased in 2022 IMP's DSI value in 2021 isthe highest in years, suggesting the company maintains inventory for a longer period of timebefore selling it out
Trang 10D Days Sales Uncollected:
a Definition:
Is a financial metric used to measure the average time it takes a company to collect money from acustomer after a sale This metric shows the average number of days a company has to wait to collectmoney from a customer
b Formula:
𝐷𝑎𝑦𝑠 𝑆𝑎𝑙𝑒𝑠 𝑈𝑛𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 = 𝑁𝑒𝑡 𝑎𝑛𝑛𝑢𝑎𝑙 𝑐𝑟𝑒𝑑𝑖𝑡 𝑠𝑎𝑙𝑒𝑠 𝐴𝑐𝑐𝑜𝑢𝑛𝑡 𝑅𝑒𝑐𝑒𝑖𝑣𝑎𝑏𝑙𝑒 * 365
c Data from selected companies:
DHG - Hau Giang Pharmaceutical Joint Stock Company
Accounts Receivable 496.020.199.824 488.071.438.874 550.503.358.957Net annual credit sales 3.755.619.311.324 4.003.163.917.775 4.676.016.007.827Days Sales
DCL - Cuu Long Pharmaceutical Joint Stock Company
Accounts Receivable 288.736.575.421 233.633.989.883 776.382.287.481
Net annual credit sales 671.246.206.966 703.634.340.577 1.015.685.512.758
Days Sales Uncollected 157,005 121,194 279,003OPC - OPC Pharmaceutical Joint Stock Company
Accounts Receivable 149.278.338.347 133.380.003.104 172.336.453.588
Net annual credit sales 965.590.544.373 1.123.727.917.160 1.171.614.107.848
Days Sales Uncollected 56,428 43,323 53,689
IMP - IMEXPHARM Pharmaceutical Joint Stock Company
Accounts Receivable 398.091.289.641 295.062.515.167 270.938.803.795Net annual credit sales 1.369.421.714.781 1.266.596.707.350 1.643.706.514.646Days Sales
d Evaluate:
Overall, companies have differences in DSU values, however, DSU values are relatively low andshow that companies are able to effectively collect money from customers:
Trang 11- DHG's DSU decreased from 2020 to 2022, indicating the company reduced wait times tocollect money from customers after a sale DSU values in the years are relatively low,showing that the company has the ability to collect money from customers quickly.
- DCL's DSU decreased significantly from 2020 to 2021, but increased sharply in 2022 DSUvalue in 2022 is the highest in years, indicating that the company has to wait longer to collectmoney from customers after the sale
- OPC's DSU decreased from 2020 to 2021, but increased again in 2022 The DSU value in
2021 is the lowest in years, showing the company's ability to collect money from customersquickly
- IMP's DSU decreases from 2020 to 2021, and continues to decrease in 2022 DSU values inall years are at a relatively low level, showing that the company has the ability to collectmoney from customers quickly
b Formula:
𝑁𝑒𝑡 𝑠𝑎𝑙𝑒𝑠
c Data from selected companies:
DHG - Hau Giang Pharmaceutical Joint Stock Company
gross margin 1,811,376,269,242 1,920,904,092,861 2,257,494,943,128Net Sales 3,755,619,311,324 4,003,163,917,775 4,676,016,007,827Cost of good sold 1,944,243,042,082 2,082,259,824,914 2,418,521,064,699gross margin ratio 48.23% 47.98% 48.27%
DCL - Cuu Long Pharmaceutical Joint Stock Company
2020 2021 2022gross margin 139,193,370,779 158,735,292,160 212,233,759,252Net Sale 624,093,643,324 654,936,735,647 946,314,827,478Cost of good sold 484,900,272,545 496,201,443,487 734,081,068,226gross margin ratio 22.30% 24.23% 22.42%
Trang 122020 2021 2022gross margin 341,317,872,141 402,199,578,080 450,423,900,833Net Sale 747,588,883,338 931,035,982,003 1,088,510,637,416Cost of good sold 406,271,011,197 528,836,403,923 638,086,736,583gross margin ratio 45.65% 43.199 41.380
IMP - IMEXPHARM Pharmaceutical Joint Stock Company
gross margin 547,045,578,338 488,001,326,263 697,355,250,216Net Sale 1,369,421,714,781 1,266,596,707,350 1,643,706,514,646Cost of good sold 822,376,136,443 778,595,381,087 946,351,264,430gross margin ratio 39.94% 38.52% 42.42%
- IMP's Gross profit margin index fluctuates from 38.52% in 2021 to 42.42% in 2022, but is in
a fairly stable range IMP shows the ability to improve gross profit and cost of goods sold in2022
B Return on assets:
a Definition:
Return on Assets (ROA) is a financial metric used to evaluate the profitability of a company's assets
It measures the company's ability to generate profit from its assets
ROA is expressed as a percentage and indicates the proportion of profit generated by the companyrelative to its total assets A higher ROA indicates that the company is using its assets efficiently togenerate profit Conversely, a lower ROA may suggest that the company is struggling to effectivelyutilize its assets to generate returns
ROA is an important financial ratio in financial analysis, helping investors and managers assess thefinancial performance of a company and compare it to other companies in the same industry or overtime